Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    NCT01218516
Previous Study | Return to List | Next Study

A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Morphotek
ClinicalTrials.gov Identifier:
NCT01218516
First received: October 7, 2010
Last updated: May 12, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2013
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)